A citation-based method for searching scientific literature

S L George, V Parmar, F Lorenzi, L V Marshall, Y Jamin, E Poon, P Angelini, L Chesler. J Exp Clin Cancer Res 2020
Times Cited: 12







List of co-cited articles
119 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The genetic landscape of high-risk neuroblastoma.
Trevor J Pugh, Olena Morozova, Edward F Attiyeh, Shahab Asgharzadeh, Jun S Wei, Daniel Auclair, Scott L Carter, Kristian Cibulskis, Megan Hanna, Adam Kiezun,[...]. Nat Genet 2013
651
50

Recent advances in neuroblastoma.
John M Maris. N Engl J Med 2010
50

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
Rachel Litman Flynn, Kelli E Cox, Maya Jeitany, Hiroaki Wakimoto, Alysia R Bryll, Neil J Ganem, Francesca Bersani, Jose R Pineda, Mario L Suvà, Cyril H Benes,[...]. Science 2015
255
50


TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
Linda J Valentijn, Jan Koster, Danny A Zwijnenburg, Nancy E Hasselt, Peter van Sluis, Richard Volckmann, Max M van Noesel, Rani E George, Godelieve A M Tytgat, Jan J Molenaar,[...]. Nat Genet 2015
204
50

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Martin Peifer, Falk Hertwig, Frederik Roels, Daniel Dreidax, Moritz Gartlgruber, Roopika Menon, Andrea Krämer, Justin L Roncaioli, Frederik Sand, Johannes M Heuckmann,[...]. Nature 2015
296
50

A mechanistic classification of clinical phenotypes in neuroblastoma.
Sandra Ackermann, Maria Cartolano, Barbara Hero, Anne Welte, Yvonne Kahlert, Andrea Roderwieser, Christoph Bartenhagen, Esther Walter, Judith Gecht, Laura Kerschke,[...]. Science 2018
90
50


Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres.
Rebecca A Dagg, Hilda A Pickett, Axel A Neumann, Christine E Napier, Jeremy D Henson, Erdahl T Teber, Jonathan W Arthur, C Patrick Reynolds, Jayne Murray, Michelle Haber,[...]. Cell Rep 2017
41
41

Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours.
David T W Jones, Ana Banito, Thomas G P Grünewald, Michelle Haber, Natalie Jäger, Marcel Kool, Till Milde, Jan J Molenaar, Arash Nabbi, Trevor J Pugh,[...]. Nat Rev Cancer 2019
49
33

Neuroblastoma.
Katherine K Matthay, John M Maris, Gudrun Schleiermacher, Akira Nakagawara, Crystal L Mackall, Lisa Diller, William A Weiss. Nat Rev Dis Primers 2016
445
33

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Isabelle Janoueix-Lerosey, Delphine Lequin, Laurence Brugières, Agnès Ribeiro, Loïc de Pontual, Valérie Combaret, Virginie Raynal, Alain Puisieux, Gudrun Schleiermacher, Gaëlle Pierron,[...]. Nature 2008
591
33

Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Edward F Attiyeh, Wendy B London, Yael P Mossé, Qun Wang, Cynthia Winter, Deepa Khazi, Patrick W McGrady, Robert C Seeger, A Thomas Look, Hiroyuki Shimada,[...]. N Engl J Med 2005
363
33

Alternative lengthening of telomeres: models, mechanisms and implications.
Anthony J Cesare, Roger R Reddel. Nat Rev Genet 2010
583
33

Systematic analysis of telomere length and somatic alterations in 31 cancer types.
Floris P Barthel, Wei Wei, Ming Tang, Emmanuel Martinez-Ledesma, Xin Hu, Samirkumar B Amin, Kadir C Akdemir, Sahil Seth, Xingzhi Song, Qianghu Wang,[...]. Nat Genet 2017
235
33

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
Jan J Molenaar, Jan Koster, Danny A Zwijnenburg, Peter van Sluis, Linda J Valentijn, Ida van der Ploeg, Mohamed Hamdi, Johan van Nes, Bart A Westerman, Jennemiek van Arkel,[...]. Nature 2012
571
33

Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Balakrishna Koneru, Gonzalo Lopez, Ahsan Farooqi, Karina L Conkrite, Thinh H Nguyen, Shawn J Macha, Apexa Modi, Jo Lynne Rokita, Eduardo Urias, Ashly Hindle,[...]. Cancer Res 2020
17
33

DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity.
Jeremy D Henson, Ying Cao, Lily I Huschtscha, Andy C Chang, Amy Y M Au, Hilda A Pickett, Roger R Reddel. Nat Biotechnol 2009
273
33

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
Nai-Kong V Cheung, Jinghui Zhang, Charles Lu, Matthew Parker, Armita Bahrami, Satish K Tickoo, Adriana Heguy, Alberto S Pappo, Sara Federico, James Dalton,[...]. JAMA 2012
253
33

Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.
Sabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, Matthias Ziehm, Umut H Toprak, Carl Herrmann, Naveed Ishaque, Konstantin Okonechnikov, Moritz Gartlgruber, Young-Gyu Park,[...]. Nat Commun 2021
6
66

MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Maged Zeineldin, Sara Federico, Xiang Chen, Yiping Fan, Beisi Xu, Elizabeth Stewart, Xin Zhou, Jongrye Jeon, Lyra Griffiths, Rosa Nguyen,[...]. Nat Commun 2020
31
33

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Thomas F Eleveld, Derek A Oldridge, Virginie Bernard, Jan Koster, Léo Colmet Daage, Sharon J Diskin, Linda Schild, Nadia Bessoltane Bentahar, Angela Bellini, Mathieu Chicard,[...]. Nat Genet 2015
275
25

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, Wendy B London, Susan G Kreissman, Helen X Chen, Malcolm Smith, Barry Anderson, Judith G Villablanca, Katherine K Matthay,[...]. N Engl J Med 2010
960
25

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Wendy B London, Victoria Castel, Tom Monclair, Peter F Ambros, Andrew D J Pearson, Susan L Cohn, Frank Berthold, Akira Nakagawara, Ruth L Ladenstein, Tomoko Iehara,[...]. J Clin Oncol 2011
161
25

Identification of ALK as a major familial neuroblastoma predisposition gene.
Yaël P Mossé, Marci Laudenslager, Luca Longo, Kristina A Cole, Andrew Wood, Edward F Attiyeh, Michael J Laquaglia, Rachel Sennett, Jill E Lynch, Patrizia Perri,[...]. Nature 2008
833
25


Oncogenic mutations of ALK kinase in neuroblastoma.
Yuyan Chen, Junko Takita, Young Lim Choi, Motohiro Kato, Miki Ohira, Masashi Sanada, Lili Wang, Manabu Soda, Akira Kikuchi, Takashi Igarashi,[...]. Nature 2008
613
25

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Navin R Pinto, Mark A Applebaum, Samuel L Volchenboum, Katherine K Matthay, Wendy B London, Peter F Ambros, Akira Nakagawara, Frank Berthold, Gudrun Schleiermacher, Julie R Park,[...]. J Clin Oncol 2015
352
25

Emergence of new ALK mutations at relapse of neuroblastoma.
Gudrun Schleiermacher, Niloufar Javanmardi, Virginie Bernard, Quentin Leroy, Julie Cappo, Thomas Rio Frio, Gaelle Pierron, Eve Lapouble, Valérie Combaret, Frank Speleman,[...]. J Clin Oncol 2014
105
25

Activating mutations in ALK provide a therapeutic target in neuroblastoma.
Rani E George, Takaomi Sanda, Megan Hanna, Stefan Fröhling, William Luther, Jianming Zhang, Yebin Ahn, Wenjun Zhou, Wendy B London, Patrick McGrady,[...]. Nature 2008
596
25

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
Sara De Brouwer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michaël Porcu, Ellen M Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebeeck, Tom Van Maerken,[...]. Clin Cancer Res 2010
181
25


Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
Christopher M Heaphy, Andrea P Subhawong, Seung-Mo Hong, Michael G Goggins, Elizabeth A Montgomery, Edward Gabrielson, George J Netto, Jonathan I Epstein, Tamara L Lotan, William H Westra,[...]. Am J Pathol 2011
293
25

Telomeres and telomerase: three decades of progress.
Jerry W Shay, Woodring E Wright. Nat Rev Genet 2019
208
25

Telomere maintenance is pivotal for high-risk neuroblastoma.
Falk Hertwig, Martin Peifer, Matthias Fischer. Cell Cycle 2016
26
25

Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
T R Yeager, A A Neumann, A Englezou, L I Huschtscha, J R Noble, R R Reddel. Cancer Res 1999
502
25

A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.
Xiao-Hui Zheng, Xin Nie, Yiming Fang, Zepeng Zhang, Yingnan Xiao, Zongwan Mao, Haiying Liu, Jian Ren, Feng Wang, Lixin Xia,[...]. J Natl Cancer Inst 2017
22
25

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.
Xiang Chen, Armita Bahrami, Alberto Pappo, John Easton, James Dalton, Erin Hedlund, David Ellison, Sheila Shurtleff, Gang Wu, Lei Wei,[...]. Cell Rep 2014
375
25

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T W Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes,[...]. Nature 2012
25

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
Sally L George, Federica Lorenzi, David King, Sabine Hartlieb, James Campbell, Helen Pemberton, Umut H Toprak, Karen Barker, Jennifer Tall, Barbara Martins da Costa,[...]. EBioMedicine 2020
12
25

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
David Clynes, Clare Jelinska, Barbara Xella, Helena Ayyub, Caroline Scott, Matthew Mitson, Stephen Taylor, Douglas R Higgs, Richard J Gibbons. Nat Commun 2015
140
25

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
N Bown, S Cotterill, M Lastowska, S O'Neill, A D Pearson, D Plantaz, M Meddeb, G Danglot, C Brinkschmidt, H Christiansen,[...]. N Engl J Med 1999
356
25

Neuroblastoma: clinical and biological approach to risk stratification and treatment.
Vanessa P Tolbert, Katherine K Matthay. Cell Tissue Res 2018
71
16

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Lori S Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R Russell, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li,[...]. Clin Cancer Res 2017
47
16

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Scott C Bresler, Daniel A Weiser, Peter J Huwe, Jin H Park, Kateryna Krytska, Hannah Ryles, Marci Laudenslager, Eric F Rappaport, Andrew C Wood, Patrick W McGrady,[...]. Cancer Cell 2014
203
16

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
R C Seeger, G M Brodeur, H Sather, A Dalton, S E Siegel, K Y Wong, D Hammond. N Engl J Med 1985
16

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Yael P Mossé, Megan S Lim, Stephan D Voss, Keith Wilner, Katherine Ruffner, Julie Laliberte, Delphine Rolland, Frank M Balis, John M Maris, Brenda J Weigel,[...]. Lancet Oncol 2013
423
16

Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Angela Bellini, Virginie Bernard, Quentin Leroy, Thomas Rio Frio, Gaelle Pierron, Valérie Combaret, Eve Lapouble, Nathalie Clement, Herve Rubie, Estelle Thebaud,[...]. Clin Cancer Res 2015
37
16

Histone deacetylase 10 promotes autophagy-mediated cell survival.
Ina Oehme, Jan-Peter Linke, Barbara C Böck, Till Milde, Marco Lodrini, Bettina Hartenstein, Inga Wiegand, Christian Eckert, Wilfried Roth, Marcel Kool,[...]. Proc Natl Acad Sci U S A 2013
126
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.